Pharmaceuticals Sector: M&A Surge, Weight-Loss Competition, and Tariff Tensions
The pharmaceutical sector in early 2026 is defined by intense competition in weight-loss treatments, significant mergers and acquisitions, and geopolitical trade tensions. Novo Nordisk and Eli Lilly are battling for market dominance, with Lilly securing approval for its oral obesity drug Foundayo and Novo Nordisk launching a tablet version of Wegovy to regain share. Meanwhile, major companies are expanding pipelines through substantial deals, including Merck’s $5.7 billion acquisition of Terns Pharma, Gilead’s purchase of Ouro Medicines, and Neurocrine’s investment in Soleno Therapeutics. Political factors heavily influence the landscape, as the Trump administration imposes new tariffs on pharmaceuticals, prompting the UK to negotiate drug pricing deals to secure exemptions. Additionally, European firms like Bayer argue for higher medicine prices in Europe to offset US-centric revenue strategies. The sector also sees strategic shifts towards AI-driven drug development, exemplified by Eli Lilly’s partnership with a Hong Kong biotech firm, and mixed clinical results from smaller players like Zealand Pharma. These developments highlight a dynamic industry balancing innovation, regulatory pressures, and global trade policies.
Wire timeline
Pharmaceuticals Sector: M&A Surge, Weight-Loss Competition, and Tariff Tensions
The pharmaceutical sector in early 2026 is defined by intense competition in weight-loss treatments, significant mergers and acquisitions, and geopolitical trade tensions. Novo Nordisk and Eli Lilly are battling for market dominance, with Lilly securing approval for its oral obesity drug Foundayo and Novo Nordisk launching a tablet version of Wegovy to regain share. Meanwhile, major companies are expanding pipelines through substantial deals, including Merck’s $5.7 billion acquisition of Terns Pharma, Gilead’s purchase of Ouro Medicines, and Neurocrine’s investment in Soleno Therapeutics. Political factors heavily influence the landscape, as the Trump administration imposes new tariffs on pharmaceuticals, prompting the UK to negotiate drug pricing deals to secure exemptions. Additionally, European firms like Bayer argue for higher medicine prices in Europe to offset US-centric revenue strategies. The sector also sees strategic shifts towards AI-driven drug development, exemplified by Eli Lilly’s partnership with a Hong Kong biotech firm, and mixed clinical results from smaller players like Zealand Pharma. These developments highlight a dynamic industry balancing innovation, regulatory pressures, and global trade policies.
ft